Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease

IF 2.3 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Neuroimaging Pub Date : 2023-09-19 DOI:10.1111/jon.13156

Carmen Gasca-Salas, Clara Trompeta, Miguel López-Aguirre, Rafael Rodríguez Rojas, Jordi Clarimon, Oriol Dols-Icardo, Shaimaa El Bounasri, Pasqualina Guida, David Mata-Marín, Frida Hernández-Fernández, Connie Marras, Lina García-Cañamaque, Isabel Plaza de las Heras, Ignacio Obeso, Lydia Vela, Beatriz Fernández-Rodríguez

{"title":"Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease","authors":"Carmen Gasca-Salas, Clara Trompeta, Miguel López-Aguirre, Rafael Rodríguez Rojas, Jordi Clarimon, Oriol Dols-Icardo, Shaimaa El Bounasri, Pasqualina Guida, David Mata-Marín, Frida Hernández-Fernández, Connie Marras, Lina García-Cañamaque, Isabel Plaza de las Heras, Ignacio Obeso, Lydia Vela, Beatriz Fernández-Rodríguez","doi":"10.1111/jon.13156","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>The microtubule-associated protein tau (MAPT) H1 homozygosity (H1/H1 haplotype) is a genetic risk factor for neurodegenerative diseases, such as Parkinson's disease (PD). MAPT H1 homozygosity has been associated with conversion to PD; however, results are conflicting since some studies did not find a strong influence. Cortical hypometabolism is associated with cognitive impairment in PD. In this study, we aimed to evaluate the metabolic pattern in nondemented PD patients MAPT H1/H1 carriers in comparison with MAPT H1/H2 haplotype. In addition, we evaluated domain-specific cognitive differences according to MAPT haplotype.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We compared a group of 26 H1/H1 and 20 H1/H2 carriers with late-onset PD. Participants underwent a comprehensive neuropsychological cognitive evaluation and a [18F]-Fluorodeoxyglucose PET-MR scan.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>MAPT H1/H1 carriers showed worse performance in the digit span forward test of attention compared to MAPT H1/H2 carriers. In the [18F]-Fluorodeoxyglucose PET comparisons, MAPT H1/H1 displayed hypometabolism in the frontal cortex, parahippocampal, and cingulate gyrus, as well as in the caudate and globus pallidus.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>PD patients MAPT H1/H1 carriers without dementia exhibit relative hypometabolism in several cortical areas as well as in the basal ganglia, and worse performance in attention than MAPT H1/H2 carriers. Longitudinal studies should assess if lower scores in attention and dysfunction in these areas are predictors of dementia in MAPT H1/H1 homozygotes.</p>\n </section>\n </div>","PeriodicalId":16399,"journal":{"name":"Journal of Neuroimaging","volume":"33 6","pages":"953-959"},"PeriodicalIF":2.3000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jon.13156","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroimaging","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jon.13156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Purpose

The microtubule-associated protein tau (MAPT) H1 homozygosity (H1/H1 haplotype) is a genetic risk factor for neurodegenerative diseases, such as Parkinson's disease (PD). MAPT H1 homozygosity has been associated with conversion to PD; however, results are conflicting since some studies did not find a strong influence. Cortical hypometabolism is associated with cognitive impairment in PD. In this study, we aimed to evaluate the metabolic pattern in nondemented PD patients MAPT H1/H1 carriers in comparison with MAPT H1/H2 haplotype. In addition, we evaluated domain-specific cognitive differences according to MAPT haplotype.

Methods

We compared a group of 26 H1/H1 and 20 H1/H2 carriers with late-onset PD. Participants underwent a comprehensive neuropsychological cognitive evaluation and a [18F]-Fluorodeoxyglucose PET-MR scan.

Results

MAPT H1/H1 carriers showed worse performance in the digit span forward test of attention compared to MAPT H1/H2 carriers. In the [18F]-Fluorodeoxyglucose PET comparisons, MAPT H1/H1 displayed hypometabolism in the frontal cortex, parahippocampal, and cingulate gyrus, as well as in the caudate and globus pallidus.

Conclusion

PD patients MAPT H1/H1 carriers without dementia exhibit relative hypometabolism in several cortical areas as well as in the basal ganglia, and worse performance in attention than MAPT H1/H2 carriers. Longitudinal studies should assess if lower scores in attention and dysfunction in these areas are predictors of dementia in MAPT H1/H1 homozygotes.

Abstract Image

查看原文本刊更多论文

帕金森病非痴呆性微管相关蛋白tau H1携带者的脑代谢降低

背景与目的微管相关蛋白tau (MAPT) H1纯合性(H1/H1单倍型)是神经退行性疾病(如帕金森病(PD))的遗传危险因素。MAPT H1纯合性与PD的转化有关;然而，由于一些研究没有发现强烈的影响，结果是相互矛盾的。皮层代谢低下与帕金森病患者的认知障碍有关。在这项研究中，我们旨在比较MAPT H1/H1单倍型和MAPT H1/H2单倍型在非痴呆PD患者中的代谢模式。此外，我们根据MAPT单倍型评估了特定领域的认知差异。方法将26例H1/H1和20例H1/H2携带者与晚发型PD患者进行比较。参与者接受了全面的神经心理学认知评估和[18F]-氟脱氧葡萄糖PET-MR扫描。结果MAPT H1/H1携带者在数字跨距前向注意测验中的表现较MAPT H1/H2携带者差。在[18F]-氟脱氧葡萄糖PET比较中，MAPT H1/H1在额叶皮质、海马旁和扣带回以及尾状和白球中表现出低代谢。结论MAPT H1/H1携带者与MAPT H1/H2携带者相比，未发生痴呆的PD患者在多个皮质区和基底节区均表现出相对低代谢，注意力表现更差。纵向研究应该评估在这些区域的注意力和功能障碍得分较低是否是MAPT H1/H1纯合子痴呆的预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroimaging 医学-核医学

CiteScore

4.70

自引率

0.00%

发文量

117

审稿时长

6-12 weeks

期刊介绍： Start reading the Journal of Neuroimaging to learn the latest neurological imaging techniques. The peer-reviewed research is written in a practical clinical context, giving you the information you need on: MRI CT Carotid Ultrasound and TCD SPECT PET Endovascular Surgical Neuroradiology Functional MRI Xenon CT and other new and upcoming neuroscientific modalities.The Journal of Neuroimaging addresses the full spectrum of human nervous system disease, including stroke, neoplasia, degenerating and demyelinating disease, epilepsy, tumors, lesions, infectious disease, cerebral vascular arterial diseases, toxic-metabolic disease, psychoses, dementias, heredo-familial disease, and trauma.Offering original research, review articles, case reports, neuroimaging CPCs, and evaluations of instruments and technology relevant to the nervous system, the Journal of Neuroimaging focuses on useful clinical developments and applications, tested techniques and interpretations, patient care, diagnostics, and therapeutics. Start reading today!